Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Veterans | 18 | 2024 | 2649 | 1.980 |
Why?
|
Phenylthiohydantoin | 1 | 2024 | 205 | 0.830 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 3 | 2019 | 477 | 0.690 |
Why?
|
Paraproteinemias | 1 | 2022 | 248 | 0.680 |
Why?
|
Receptors, Transforming Growth Factor beta | 2 | 2019 | 302 | 0.650 |
Why?
|
Nitriles | 1 | 2024 | 971 | 0.650 |
Why?
|
Ouabain | 2 | 2016 | 247 | 0.640 |
Why?
|
Benzamides | 1 | 2024 | 1370 | 0.620 |
Why?
|
Myofibroblasts | 4 | 2019 | 223 | 0.610 |
Why?
|
Cardiac Glycosides | 1 | 2016 | 29 | 0.530 |
Why?
|
Digoxin | 1 | 2016 | 246 | 0.480 |
Why?
|
Prodrugs | 1 | 2015 | 261 | 0.430 |
Why?
|
Multiple Myeloma | 4 | 2024 | 5146 | 0.420 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2015 | 621 | 0.390 |
Why?
|
Transforming Growth Factor beta | 3 | 2019 | 1962 | 0.360 |
Why?
|
Fibroblasts | 3 | 2019 | 4141 | 0.360 |
Why?
|
Drug Discovery | 2 | 2016 | 1051 | 0.360 |
Why?
|
Venous Thromboembolism | 4 | 2024 | 1866 | 0.350 |
Why?
|
United States Department of Veterans Affairs | 3 | 2024 | 928 | 0.340 |
Why?
|
Plasma Cells | 3 | 2023 | 599 | 0.320 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3615 | 0.290 |
Why?
|
Natural Language Processing | 3 | 2024 | 1163 | 0.270 |
Why?
|
Neoplasms | 9 | 2024 | 22173 | 0.270 |
Why?
|
Lung | 4 | 2019 | 10002 | 0.240 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 3 | 2016 | 484 | 0.230 |
Why?
|
Algorithms | 4 | 2024 | 14032 | 0.210 |
Why?
|
Androstenes | 1 | 2024 | 181 | 0.210 |
Why?
|
Pulmonary Fibrosis | 3 | 2019 | 505 | 0.200 |
Why?
|
Cell Differentiation | 3 | 2019 | 11530 | 0.200 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1896 | 0.190 |
Why?
|
Disulfiram | 1 | 2021 | 63 | 0.190 |
Why?
|
Technology | 1 | 2024 | 292 | 0.190 |
Why?
|
Frail Elderly | 2 | 2023 | 765 | 0.190 |
Why?
|
Retrospective Studies | 17 | 2024 | 80646 | 0.180 |
Why?
|
United States | 15 | 2024 | 72335 | 0.180 |
Why?
|
Patient Identification Systems | 1 | 2020 | 75 | 0.180 |
Why?
|
Vaccination | 6 | 2023 | 3384 | 0.180 |
Why?
|
Tannins | 1 | 2019 | 13 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2021 | 315 | 0.170 |
Why?
|
Humans | 53 | 2024 | 761572 | 0.170 |
Why?
|
Workflow | 2 | 2024 | 851 | 0.170 |
Why?
|
HIV-1 | 3 | 2016 | 6863 | 0.160 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13382 | 0.150 |
Why?
|
Melanoma | 3 | 2022 | 5709 | 0.150 |
Why?
|
Electronic Health Records | 3 | 2024 | 4811 | 0.150 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5336 | 0.150 |
Why?
|
Interleukin-10 | 1 | 2022 | 1175 | 0.140 |
Why?
|
Venous Thrombosis | 2 | 2024 | 1303 | 0.140 |
Why?
|
Integrase Inhibitors | 1 | 2016 | 12 | 0.130 |
Why?
|
Cardiotonic Agents | 2 | 2019 | 539 | 0.130 |
Why?
|
Virus Diseases | 1 | 2022 | 718 | 0.130 |
Why?
|
Antifibrinolytic Agents | 1 | 2019 | 292 | 0.130 |
Why?
|
Antiviral Agents | 5 | 2024 | 3060 | 0.130 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1410 | 0.130 |
Why?
|
Ribonuclease H | 1 | 2015 | 50 | 0.120 |
Why?
|
Pandemics | 4 | 2023 | 8656 | 0.120 |
Why?
|
Psoriasis | 1 | 2023 | 950 | 0.120 |
Why?
|
HIV Reverse Transcriptase | 1 | 2016 | 212 | 0.120 |
Why?
|
Lymphoma | 1 | 2024 | 1901 | 0.120 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2015 | 293 | 0.120 |
Why?
|
HIV Integrase | 1 | 2016 | 121 | 0.120 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5315 | 0.120 |
Why?
|
Noscapine | 1 | 2014 | 2 | 0.120 |
Why?
|
Learning | 1 | 2024 | 1740 | 0.120 |
Why?
|
Antitussive Agents | 1 | 2014 | 18 | 0.120 |
Why?
|
RNA, Viral | 1 | 2022 | 2846 | 0.120 |
Why?
|
Occupational Health | 1 | 2020 | 806 | 0.110 |
Why?
|
Receptors, Prostaglandin E | 1 | 2014 | 56 | 0.110 |
Why?
|
Fibrosis | 2 | 2019 | 2049 | 0.110 |
Why?
|
Aged | 14 | 2024 | 169310 | 0.110 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4915 | 0.110 |
Why?
|
Cyclooxygenase 2 | 1 | 2016 | 597 | 0.110 |
Why?
|
Adrenomedullin | 1 | 2013 | 85 | 0.110 |
Why?
|
Small Molecule Libraries | 2 | 2016 | 733 | 0.110 |
Why?
|
Pulmonary Embolism | 2 | 2024 | 2567 | 0.100 |
Why?
|
Cells, Cultured | 3 | 2019 | 18965 | 0.100 |
Why?
|
Indoles | 1 | 2021 | 1833 | 0.100 |
Why?
|
Veterans Health | 2 | 2024 | 215 | 0.100 |
Why?
|
Cohort Studies | 7 | 2023 | 41493 | 0.100 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2897 | 0.100 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13642 | 0.100 |
Why?
|
Skin Neoplasms | 2 | 2021 | 5821 | 0.090 |
Why?
|
Immunotherapy | 2 | 2024 | 4652 | 0.090 |
Why?
|
Influenza Vaccines | 1 | 2018 | 768 | 0.090 |
Why?
|
Risk Factors | 9 | 2024 | 74213 | 0.090 |
Why?
|
Dexamethasone | 3 | 2023 | 1948 | 0.090 |
Why?
|
DNA Primers | 1 | 2015 | 2819 | 0.090 |
Why?
|
Dendrimers | 1 | 2010 | 72 | 0.090 |
Why?
|
Software | 2 | 2023 | 4434 | 0.090 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58986 | 0.090 |
Why?
|
Cell Death | 1 | 2015 | 1679 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2016 | 3597 | 0.090 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2016 | 515 | 0.090 |
Why?
|
Dementia | 1 | 2024 | 2689 | 0.080 |
Why?
|
Down-Regulation | 1 | 2016 | 2919 | 0.080 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11121 | 0.080 |
Why?
|
Hospitals, Veterans | 2 | 2022 | 395 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2422 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2942 | 0.080 |
Why?
|
Air Pollution | 1 | 2022 | 2359 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4319 | 0.080 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3763 | 0.080 |
Why?
|
Medical Records | 2 | 2023 | 1408 | 0.070 |
Why?
|
Virus Replication | 1 | 2015 | 2435 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
Male | 15 | 2024 | 360842 | 0.070 |
Why?
|
Depressive Disorder, Major | 1 | 2024 | 4761 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3201 | 0.070 |
Why?
|
Signal Transduction | 3 | 2019 | 23447 | 0.070 |
Why?
|
Prognosis | 2 | 2023 | 29629 | 0.060 |
Why?
|
Phosphorylation | 1 | 2016 | 8321 | 0.060 |
Why?
|
Middle Aged | 9 | 2024 | 220920 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3769 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2018 | 7593 | 0.060 |
Why?
|
Age Factors | 1 | 2021 | 18398 | 0.060 |
Why?
|
Gene Expression | 1 | 2016 | 7581 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 3597 | 0.050 |
Why?
|
Bleomycin | 2 | 2014 | 494 | 0.050 |
Why?
|
Knowledge | 1 | 2024 | 177 | 0.050 |
Why?
|
Prostatic Neoplasms | 1 | 2024 | 11122 | 0.050 |
Why?
|
Proto-Oncogene Protein c-ets-1 | 1 | 2021 | 63 | 0.050 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 1 | 2021 | 104 | 0.040 |
Why?
|
Oxygen | 2 | 2022 | 4227 | 0.040 |
Why?
|
Incidence | 3 | 2024 | 21355 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.040 |
Why?
|
Anti-HIV Agents | 1 | 2016 | 4527 | 0.040 |
Why?
|
RNA-Binding Protein EWS | 1 | 2021 | 210 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2022 | 696 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 616 | 0.040 |
Why?
|
Female | 12 | 2024 | 392686 | 0.040 |
Why?
|
Systems Integration | 1 | 2020 | 426 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2024 | 12463 | 0.040 |
Why?
|
Hospitalization | 3 | 2022 | 10721 | 0.040 |
Why?
|
Attitude | 1 | 2023 | 775 | 0.040 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 935 | 0.040 |
Why?
|
Treatment Outcome | 1 | 2024 | 64684 | 0.040 |
Why?
|
SEER Program | 1 | 2022 | 1450 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2021 | 571 | 0.030 |
Why?
|
Hemoglobins | 1 | 2023 | 1526 | 0.030 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2018 | 545 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1089 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8224 | 0.030 |
Why?
|
Immunoglobulin A | 1 | 2018 | 978 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1893 | 0.030 |
Why?
|
Mice | 6 | 2021 | 81533 | 0.030 |
Why?
|
Hydroxyproline | 1 | 2014 | 110 | 0.030 |
Why?
|
Adult | 6 | 2024 | 221203 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2023 | 1809 | 0.030 |
Why?
|
Receptor Activity-Modifying Protein 2 | 1 | 2013 | 3 | 0.030 |
Why?
|
Calcitonin Receptor-Like Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
Steroids | 1 | 2019 | 929 | 0.030 |
Why?
|
Iloprost | 1 | 2013 | 25 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 641 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2021 | 1609 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3208 | 0.030 |
Why?
|
Animals | 7 | 2021 | 168467 | 0.030 |
Why?
|
Luciferases | 1 | 2014 | 714 | 0.020 |
Why?
|
Risk Assessment | 2 | 2024 | 23996 | 0.020 |
Why?
|
Medical Oncology | 1 | 2024 | 2321 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2297 | 0.020 |
Why?
|
Muscle, Smooth | 1 | 2015 | 926 | 0.020 |
Why?
|
Potassium | 1 | 2015 | 1311 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1749 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16986 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2022 | 4352 | 0.020 |
Why?
|
Alcoholism | 1 | 2021 | 1973 | 0.020 |
Why?
|
Particulate Matter | 1 | 2022 | 2605 | 0.020 |
Why?
|
Drug Stability | 1 | 2010 | 291 | 0.020 |
Why?
|
Sodium | 1 | 2015 | 1588 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2015 | 2677 | 0.020 |
Why?
|
Molecular Conformation | 1 | 2010 | 544 | 0.020 |
Why?
|
Herpesvirus 2, Human | 1 | 2010 | 191 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15601 | 0.020 |
Why?
|
Cyclic AMP | 1 | 2013 | 1463 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2015 | 3792 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2019 | 22172 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7529 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2021 | 9541 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2010 | 486 | 0.020 |
Why?
|
Microtubules | 1 | 2014 | 1074 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9326 | 0.020 |
Why?
|
Astrocytes | 1 | 2015 | 1346 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54426 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7396 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2018 | 3156 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 12794 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2018 | 4544 | 0.020 |
Why?
|
Comorbidity | 1 | 2021 | 10508 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16592 | 0.020 |
Why?
|
HIV Envelope Protein gp120 | 1 | 2010 | 914 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.020 |
Why?
|
Lysine | 1 | 2010 | 993 | 0.020 |
Why?
|
Receptors, CXCR4 | 1 | 2010 | 727 | 0.020 |
Why?
|
Actins | 1 | 2013 | 2050 | 0.020 |
Why?
|
Genomics | 1 | 2021 | 5821 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10448 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 2010 | 3076 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2015 | 8181 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15732 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13510 | 0.010 |
Why?
|
Medicare | 1 | 2022 | 6770 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15843 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9610 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2015 | 3677 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11742 | 0.010 |
Why?
|
Inflammation | 1 | 2022 | 10773 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12129 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5439 | 0.010 |
Why?
|
DNA | 1 | 2014 | 7213 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26127 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18253 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30054 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39970 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11904 | 0.010 |
Why?
|
Child | 1 | 2022 | 80156 | 0.010 |
Why?
|
Brain | 1 | 2015 | 27120 | 0.000 |
Why?
|
Concepts
(219)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_